RD162

SKU: orb1306218

Description

RD162 is a non-steroidal antiandrogen that selectively binds to and inhibits the androgen receptor (AR). It is a research tool used in vitro and in vivo to study prostate cancer and androgen receptor signaling pathways.

Research Area

Metabolism Research

Key Properties

• CAS Number: 915087-27-3
• MW: 476.45
• Purity: 99.71% (May vary between batches)
• Formula: C₂₂H₁₆F₄N₄O₂S
• SMILES: O=C1C2(N(C(=S)N1C3=CC(C(F)(F)F)=C(C#N)C=C3)C4=CC(F)=C(C(NC)=O)C=C4)CCC2
• Target: Androgen Receptor
• Solubility: DMSO:50 mg/mL (104.94 mM)

Bioactivity

• In Vivo:
  RD162 (20 mg/kg) is ∼50 percent bioavailable after oral delivery with a serum half-life of about 30 hours. RD162 (10 mg/kg; oral gavage) causes all tumors regressed. RD162 (0.1, 1, 10 mg/kg; oral gavage) consistently reduces luciferase activity with 10 mg/kg/day human LNCaP/AR xenografts grown in castrated male mice whereas lower doses of 0.1 and 1.0 mg/kg/day has minimal effect. RD162 substantially reduces cellular proliferation after 5 days.
  Read more...
• In Vitro:
  RD162 has little to no binding to the progesterone, estrogen, or glucocorticoid receptors. RD162 (1-10 μM) suppressed growth and induces apoptosis in the human prostate cancer cell line VCaP which had endogenous AR gene amplification.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AndrogenReceptor, Androgen Receptor, diarylthiohydantoin, castration, inhibit, NSAA, LNCaP, Inhibitor, orally, RD-162, RD 162, RD162, prostate, VCaP

Compound Identifiers

PubChem CID

11957756